Share Price and Basic Stock Data
Last Updated: January 1, 2026, 7:19 pm
| PEG Ratio | -0.52 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ambalal Sarabhai Enterprises Ltd operates within the pharmaceuticals sector, with its stock price reported at ₹28.6 and a market capitalization of ₹219 Cr. In terms of revenue, the company recorded sales of ₹170 Cr for the fiscal year ending March 2023, which slightly increased to ₹173 Cr in March 2024 and further rose to ₹196 Cr in March 2025. The quarterly sales figures indicate variability, with a high of ₹54.35 Cr in March 2024 and a low of ₹35.36 Cr in December 2022. Notably, the company reported a significant sales recovery in the March 2024 quarter, which marked a pivotal point in revenue generation. The trailing twelve months (TTM) sales stood at ₹196 Cr, reflecting the overall stability in revenue generation despite occasional fluctuations in quarterly performance. This performance positions Ambalal Sarabhai Enterprises in a competitive landscape, especially considering the growing demand for pharmaceutical products in India.
Profitability and Efficiency Metrics
Profitability metrics for Ambalal Sarabhai Enterprises indicate a mixed performance. The operating profit margin (OPM) stood at 0.81% for the latest reporting period, with fluctuations throughout the previous quarters, including a negative margin of -11.00% in June 2023. The net profit for the fiscal year ending March 2023 was reported at ₹11 Cr, which showcased a decline from ₹47 Cr in March 2022, highlighting challenges in maintaining profitability. The company’s return on equity (ROE) was recorded at 6.25%, while the return on capital employed (ROCE) was at 9.12%. These figures suggest that the company is generating moderate returns on its investments, but the efficiency ratios, particularly the operating profit margins, indicate areas needing improvement. The interest coverage ratio of 4.56x demonstrates a reasonable capacity to meet interest obligations, yet the overall profitability remains constrained by fluctuating operational performance.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ambalal Sarabhai Enterprises reflects a total borrowing of ₹47 Cr against reserves of ₹71 Cr, indicating a relatively low debt burden with a debt-to-equity ratio of 0.34. The company’s current ratio stood at 0.98, suggesting a tight liquidity position. The book value per share increased to ₹18.27 in March 2025 from ₹17.90 in March 2024, signaling gradual improvement in net asset value. However, the cash conversion cycle (CCC) reported at -2 days suggests efficient management of working capital, with debtor days at 59 and inventory days at 62. The enterprise value was recorded at ₹305.67 Cr, and the price-to-book value ratio stood at 1.92x, indicating that the market is valuing the company at a premium over its book value. Overall, while the balance sheet appears robust, the liquidity ratios reveal potential challenges in meeting short-term obligations.
Shareholding Pattern and Investor Confidence
Ambalal Sarabhai Enterprises has a diversified shareholding pattern, with promoters holding 31.35% of the equity as of September 2025. The public holds a substantial 68.32%, while institutional investors (FIIs and DIIs) have minimal stakes, standing at 0.34% and 0.00%, respectively. The total number of shareholders decreased to 170,015, reflecting a gradual decline in investor participation. The consistent promoter stake since March 2023 indicates a steady commitment by the original owners, potentially instilling confidence among retail investors. However, the lack of significant institutional interest may raise concerns regarding the company’s growth prospects. The historical data suggests that despite fluctuations in share price, the promoter’s stable holding can be interpreted as a vote of confidence in the company’s long-term strategies.
Outlook, Risks, and Final Insight
The outlook for Ambalal Sarabhai Enterprises hinges on its ability to stabilize profitability and enhance operational efficiency amidst the competitive pharmaceutical landscape. Key strengths include a relatively low debt level, a diverse shareholder base, and improvements in sales growth. However, risks remain, including the volatility in operating margins and the company’s reliance on a fluctuating sales environment. Additionally, the company faces challenges in attracting institutional investors, which could limit future growth capital. To maintain momentum, Ambalal Sarabhai Enterprises must focus on improving profit margins and managing expenses effectively. Should the company succeed in these endeavors, it may pave the way for improved investor confidence and sustainable growth in the forthcoming quarters.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 131 Cr. | 104 | 217/84.3 | 29.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,800 Cr. | 441 | 479/192 | 99.4 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.8 Cr. | 48.2 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.7 Cr. | 36.0 | 36.6/17.0 | 125 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,121.68 Cr | 1,146.12 | 53.36 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46.84 | 35.36 | 44.44 | 36.10 | 40.01 | 43.11 | 54.35 | 40.70 | 44.70 | 45.97 | 64.81 | 40.34 | 44.45 |
| Expenses | 46.11 | 33.79 | 41.09 | 40.07 | 39.00 | 40.58 | 49.70 | 40.23 | 42.16 | 46.67 | 59.51 | 38.88 | 44.09 |
| Operating Profit | 0.73 | 1.57 | 3.35 | -3.97 | 1.01 | 2.53 | 4.65 | 0.47 | 2.54 | -0.70 | 5.30 | 1.46 | 0.36 |
| OPM % | 1.56% | 4.44% | 7.54% | -11.00% | 2.52% | 5.87% | 8.56% | 1.15% | 5.68% | -1.52% | 8.18% | 3.62% | 0.81% |
| Other Income | 2.38 | 3.06 | 5.71 | 1.37 | 2.85 | 1.63 | 4.79 | 2.30 | 2.80 | 5.76 | -5.37 | 8.36 | 1.62 |
| Interest | 0.45 | 0.56 | 0.99 | 0.95 | 0.92 | 0.99 | 0.90 | 0.95 | 1.22 | 1.14 | 0.96 | 1.01 | 0.96 |
| Depreciation | 0.62 | 0.61 | 0.92 | 1.05 | 1.14 | 1.13 | 0.25 | 0.98 | 1.01 | 0.99 | 1.02 | 0.88 | 1.06 |
| Profit before tax | 2.04 | 3.46 | 7.15 | -4.60 | 1.80 | 2.04 | 8.29 | 0.84 | 3.11 | 2.93 | -2.05 | 7.93 | -0.04 |
| Tax % | 50.00% | 12.72% | 20.14% | 5.87% | 40.00% | 34.31% | -8.69% | 59.52% | 15.76% | 23.89% | -86.83% | -3.66% | 1,300.00% |
| Net Profit | 1.02 | 3.01 | 5.71 | -4.87 | 1.08 | 1.33 | 9.02 | 0.35 | 2.62 | 2.23 | -0.27 | 8.22 | -0.56 |
| EPS in Rs | 0.13 | 0.39 | 0.75 | -0.64 | 0.14 | 0.17 | 1.18 | 0.05 | 0.34 | 0.29 | -0.04 | 1.07 | -0.07 |
Last Updated: December 28, 2025, 5:29 am
Below is a detailed analysis of the quarterly data for Ambalal Sarabhai Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 44.45 Cr.. The value appears strong and on an upward trend. It has increased from 40.34 Cr. (Jun 2025) to 44.45 Cr., marking an increase of 4.11 Cr..
- For Expenses, as of Sep 2025, the value is 44.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.88 Cr. (Jun 2025) to 44.09 Cr., marking an increase of 5.21 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.36 Cr.. The value appears to be declining and may need further review. It has decreased from 1.46 Cr. (Jun 2025) to 0.36 Cr., marking a decrease of 1.10 Cr..
- For OPM %, as of Sep 2025, the value is 0.81%. The value appears to be declining and may need further review. It has decreased from 3.62% (Jun 2025) to 0.81%, marking a decrease of 2.81%.
- For Other Income, as of Sep 2025, the value is 1.62 Cr.. The value appears to be declining and may need further review. It has decreased from 8.36 Cr. (Jun 2025) to 1.62 Cr., marking a decrease of 6.74 Cr..
- For Interest, as of Sep 2025, the value is 0.96 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.01 Cr. (Jun 2025) to 0.96 Cr., marking a decrease of 0.05 Cr..
- For Depreciation, as of Sep 2025, the value is 1.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.88 Cr. (Jun 2025) to 1.06 Cr., marking an increase of 0.18 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 7.93 Cr. (Jun 2025) to -0.04 Cr., marking a decrease of 7.97 Cr..
- For Tax %, as of Sep 2025, the value is 1,300.00%. The value appears to be increasing, which may not be favorable. It has increased from -3.66% (Jun 2025) to 1,300.00%, marking an increase of 1,303.66%.
- For Net Profit, as of Sep 2025, the value is -0.56 Cr.. The value appears to be declining and may need further review. It has decreased from 8.22 Cr. (Jun 2025) to -0.56 Cr., marking a decrease of 8.78 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.07. The value appears to be declining and may need further review. It has decreased from 1.07 (Jun 2025) to -0.07, marking a decrease of 1.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 105 | 124 | 132 | 134 | 125 | 150 | 133 | 163 | 197 | 170 | 173 | 196 | 196 |
| Expenses | 112 | 129 | 145 | 137 | 137 | 144 | 136 | 165 | 171 | 162 | 167 | 187 | 189 |
| Operating Profit | -7 | -4 | -13 | -3 | -12 | 6 | -3 | -2 | 25 | 8 | 6 | 9 | 6 |
| OPM % | -7% | -3% | -10% | -2% | -9% | 4% | -2% | -1% | 13% | 5% | 3% | 5% | 3% |
| Other Income | 2 | 13 | 95 | -2 | 25 | 8 | 24 | 40 | 33 | 12 | 10 | 5 | 10 |
| Interest | 11 | 10 | 4 | 5 | 3 | 3 | 4 | 3 | 2 | 3 | 6 | 5 | 4 |
| Depreciation | 3 | 5 | 17 | 4 | 2 | 2 | 3 | 2 | 2 | 3 | 4 | 4 | 4 |
| Profit before tax | -20 | -6 | 62 | -14 | 8 | 8 | 15 | 33 | 54 | 15 | 7 | 5 | 9 |
| Tax % | 3% | 13% | 22% | 34% | 84% | 48% | 6% | 10% | 13% | 25% | 15% | -2% | |
| Net Profit | -20 | -7 | 48 | -18 | 1 | 4 | 14 | 29 | 47 | 11 | 6 | 5 | 10 |
| EPS in Rs | -2.64 | -0.87 | 6.28 | -2.38 | 0.17 | 0.55 | 1.83 | 3.83 | 6.16 | 1.49 | 0.74 | 0.64 | 1.25 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 65.00% | 785.71% | -137.50% | 105.56% | 300.00% | 250.00% | 107.14% | 62.07% | -76.60% | -45.45% | -16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 720.71% | -923.21% | 243.06% | 194.44% | -50.00% | -142.86% | -45.07% | -138.66% | 31.14% | 28.79% |
Ambalal Sarabhai Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 8% |
| 3 Years: | 0% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | -9% |
| 3 Years: | -37% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 7% |
| 3 Years: | 1% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 13% |
| 3 Years: | 7% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 10, 2025, 3:47 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
| Reserves | -79 | -86 | -38 | -51 | -50 | -46 | -32 | -3 | 43 | 54 | 60 | 63 | 71 |
| Borrowings | 42 | 46 | 47 | 42 | 43 | 40 | 31 | 28 | 27 | 45 | 46 | 51 | 47 |
| Other Liabilities | 128 | 132 | 94 | 93 | 128 | 144 | 111 | 108 | 84 | 70 | 67 | 79 | 66 |
| Total Liabilities | 167 | 169 | 180 | 160 | 197 | 214 | 186 | 210 | 231 | 246 | 250 | 270 | 260 |
| Fixed Assets | 94 | 91 | 72 | 72 | 59 | 58 | 57 | 57 | 58 | 85 | 88 | 87 | 87 |
| CWIP | 0 | 1 | 9 | 3 | 14 | 24 | 0 | 1 | 12 | 4 | 0 | 0 | 0 |
| Investments | 1 | 1 | 8 | 5 | 5 | 9 | 18 | 27 | 33 | 32 | 29 | 32 | 32 |
| Other Assets | 71 | 76 | 92 | 80 | 119 | 123 | 110 | 125 | 128 | 125 | 133 | 151 | 141 |
| Total Assets | 167 | 169 | 180 | 160 | 197 | 214 | 186 | 210 | 231 | 246 | 250 | 270 | 260 |
Below is a detailed analysis of the balance sheet data for Ambalal Sarabhai Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 77.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 77.00 Cr..
- For Reserves, as of Sep 2025, the value is 71.00 Cr.. The value appears strong and on an upward trend. It has increased from 63.00 Cr. (Mar 2025) to 71.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Sep 2025, the value is 47.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 51.00 Cr. (Mar 2025) to 47.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 66.00 Cr.. The value appears to be improving (decreasing). It has decreased from 79.00 Cr. (Mar 2025) to 66.00 Cr., marking a decrease of 13.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 260.00 Cr.. The value appears to be improving (decreasing). It has decreased from 270.00 Cr. (Mar 2025) to 260.00 Cr., marking a decrease of 10.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 87.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 87.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 32.00 Cr..
- For Other Assets, as of Sep 2025, the value is 141.00 Cr.. The value appears to be declining and may need further review. It has decreased from 151.00 Cr. (Mar 2025) to 141.00 Cr., marking a decrease of 10.00 Cr..
- For Total Assets, as of Sep 2025, the value is 260.00 Cr.. The value appears to be declining and may need further review. It has decreased from 270.00 Cr. (Mar 2025) to 260.00 Cr., marking a decrease of 10.00 Cr..
Notably, the Reserves (71.00 Cr.) exceed the Borrowings (47.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -49.00 | -50.00 | -60.00 | -45.00 | -55.00 | -34.00 | -34.00 | -30.00 | -2.00 | -37.00 | -40.00 | -42.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 74 | 83 | 79 | 100 | 84 | 79 | 87 | 52 | 59 | 55 | 82 |
| Inventory Days | 95 | 86 | 72 | 66 | 75 | 61 | 76 | 58 | 48 | 62 | 58 | 75 |
| Days Payable | 178 | 139 | 135 | 138 | 207 | 191 | 184 | 184 | 151 | 131 | 133 | 158 |
| Cash Conversion Cycle | 12 | 22 | 20 | 6 | -32 | -46 | -29 | -39 | -50 | -10 | -19 | -2 |
| Working Capital Days | -347 | -318 | -156 | -185 | -187 | -190 | -140 | -88 | -25 | -43 | -35 | -25 |
| ROCE % | -16% | -19% | -44% | -1% | -5% | 16% | 25% | 18% | 34% | 11% | 7% | 9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| Diluted EPS (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| Cash EPS (Rs.) | 1.08 | 1.56 | 1.94 | 5.63 | 2.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.27 | 17.90 | 17.09 | 15.64 | 9.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.27 | 17.90 | 17.09 | 15.64 | 9.64 |
| Revenue From Operations / Share (Rs.) | 25.60 | 22.65 | 22.22 | 25.67 | 21.35 |
| PBDIT / Share (Rs.) | 2.54 | 2.18 | 2.75 | 8.73 | 3.76 |
| PBIT / Share (Rs.) | 2.02 | 1.71 | 2.39 | 8.43 | 3.44 |
| PBT / Share (Rs.) | 0.54 | 1.22 | 2.07 | 6.23 | 3.06 |
| Net Profit / Share (Rs.) | 0.56 | 1.10 | 1.58 | 5.32 | 2.64 |
| NP After MI And SOA / Share (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| PBDIT Margin (%) | 9.92 | 9.61 | 12.36 | 34.00 | 17.59 |
| PBIT Margin (%) | 7.87 | 7.55 | 10.74 | 32.82 | 16.11 |
| PBT Margin (%) | 2.13 | 5.39 | 9.31 | 24.28 | 14.31 |
| Net Profit Margin (%) | 2.18 | 4.83 | 7.13 | 20.73 | 12.36 |
| NP After MI And SOA Margin (%) | 2.51 | 3.27 | 6.51 | 23.99 | 17.93 |
| Return on Networth / Equity (%) | 3.52 | 4.14 | 8.47 | 39.39 | 39.72 |
| Return on Capital Employeed (%) | 10.33 | 8.86 | 12.15 | 51.65 | 32.36 |
| Return On Assets (%) | 1.82 | 2.27 | 4.51 | 20.48 | 13.97 |
| Long Term Debt / Equity (X) | 0.05 | 0.06 | 0.13 | 0.02 | 0.07 |
| Total Debt / Equity (X) | 0.34 | 0.32 | 0.30 | 0.21 | 0.35 |
| Asset Turnover Ratio (%) | 0.75 | 0.69 | 0.71 | 0.00 | 0.00 |
| Current Ratio (X) | 0.98 | 1.16 | 1.23 | 1.14 | 0.93 |
| Quick Ratio (X) | 0.78 | 1.00 | 1.04 | 0.99 | 0.81 |
| Inventory Turnover Ratio (X) | 9.86 | 0.90 | 0.80 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 4.56 | 4.44 | 8.64 | 39.34 | 9.76 |
| Interest Coverage Ratio (Post Tax) (X) | 3.65 | 3.23 | 5.98 | 33.88 | 7.86 |
| Enterprise Value (Cr.) | 305.67 | 360.72 | 169.24 | 264.81 | 129.80 |
| EV / Net Operating Revenue (X) | 1.56 | 2.08 | 0.99 | 1.35 | 0.79 |
| EV / EBITDA (X) | 15.70 | 21.61 | 8.04 | 3.96 | 4.51 |
| MarketCap / Net Operating Revenue (X) | 1.37 | 2.01 | 0.92 | 1.36 | 0.82 |
| Price / BV (X) | 1.92 | 2.54 | 1.20 | 2.23 | 1.83 |
| Price / Net Operating Revenue (X) | 1.37 | 2.01 | 0.92 | 1.36 | 0.82 |
| EarningsYield | 0.01 | 0.01 | 0.07 | 0.17 | 0.21 |
After reviewing the key financial ratios for Ambalal Sarabhai Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 3. It has decreased from 1.56 (Mar 24) to 1.08, marking a decrease of 0.48.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.27. It has increased from 17.90 (Mar 24) to 18.27, marking an increase of 0.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.27. It has increased from 17.90 (Mar 24) to 18.27, marking an increase of 0.37.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 25.60. It has increased from 22.65 (Mar 24) to 25.60, marking an increase of 2.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.54. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 2.54, marking an increase of 0.36.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.02. This value is within the healthy range. It has increased from 1.71 (Mar 24) to 2.02, marking an increase of 0.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.54. This value is within the healthy range. It has decreased from 1.22 (Mar 24) to 0.54, marking a decrease of 0.68.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.56. This value is below the healthy minimum of 2. It has decreased from 1.10 (Mar 24) to 0.56, marking a decrease of 0.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 2. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For PBDIT Margin (%), as of Mar 25, the value is 9.92. This value is below the healthy minimum of 10. It has increased from 9.61 (Mar 24) to 9.92, marking an increase of 0.31.
- For PBIT Margin (%), as of Mar 25, the value is 7.87. This value is below the healthy minimum of 10. It has increased from 7.55 (Mar 24) to 7.87, marking an increase of 0.32.
- For PBT Margin (%), as of Mar 25, the value is 2.13. This value is below the healthy minimum of 10. It has decreased from 5.39 (Mar 24) to 2.13, marking a decrease of 3.26.
- For Net Profit Margin (%), as of Mar 25, the value is 2.18. This value is below the healthy minimum of 5. It has decreased from 4.83 (Mar 24) to 2.18, marking a decrease of 2.65.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.51. This value is below the healthy minimum of 8. It has decreased from 3.27 (Mar 24) to 2.51, marking a decrease of 0.76.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.52. This value is below the healthy minimum of 15. It has decreased from 4.14 (Mar 24) to 3.52, marking a decrease of 0.62.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has increased from 8.86 (Mar 24) to 10.33, marking an increase of 1.47.
- For Return On Assets (%), as of Mar 25, the value is 1.82. This value is below the healthy minimum of 5. It has decreased from 2.27 (Mar 24) to 1.82, marking a decrease of 0.45.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has increased from 0.32 (Mar 24) to 0.34, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.69 (Mar 24) to 0.75, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1.5. It has decreased from 1.16 (Mar 24) to 0.98, marking a decrease of 0.18.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.00 (Mar 24) to 0.78, marking a decrease of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.86. This value exceeds the healthy maximum of 8. It has increased from 0.90 (Mar 24) to 9.86, marking an increase of 8.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.56. This value is within the healthy range. It has increased from 4.44 (Mar 24) to 4.56, marking an increase of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.65. This value is within the healthy range. It has increased from 3.23 (Mar 24) to 3.65, marking an increase of 0.42.
- For Enterprise Value (Cr.), as of Mar 25, the value is 305.67. It has decreased from 360.72 (Mar 24) to 305.67, marking a decrease of 55.05.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.56, marking a decrease of 0.52.
- For EV / EBITDA (X), as of Mar 25, the value is 15.70. This value exceeds the healthy maximum of 15. It has decreased from 21.61 (Mar 24) to 15.70, marking a decrease of 5.91.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.37, marking a decrease of 0.64.
- For Price / BV (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.92, marking a decrease of 0.62.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.37, marking a decrease of 0.64.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ambalal Sarabhai Enterprises Ltd:
- Net Profit Margin: 2.18%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.33% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.52% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 14.2 (Industry average Stock P/E: 53.36)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.34
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.18%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shanti Sadan, Mirzapur Road, Ahmedabad Gujarat 380001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kartikeya V Sarabhai | Executive Chairman |
| Mr. Mohal K Sarabhai | Managing Director |
| Ms. Chaula M Shastri | Whole Time Director |
| Dr. Pushpa Robin | Independent Director |
| Mr. Mayur Swadia | Independent Director |
| Mr. Satyen Dave | Independent Director |
| Mr. Brijesh Khandelwal | Independent Director |
| Mr. Govindprasad Namdeo | Independent Director |
| Mr. Ajay Mayor | Nominee Director |
| Mr. Bharatendu Jani | Nominee Director |
FAQ
What is the intrinsic value of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd's intrinsic value (as of 01 January 2026) is ₹13.90 which is 51.90% lower the current market price of ₹28.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹221 Cr. market cap, FY2025-2026 high/low of ₹60.0/26.0, reserves of ₹71 Cr, and liabilities of ₹260 Cr.
What is the Market Cap of Ambalal Sarabhai Enterprises Ltd?
The Market Cap of Ambalal Sarabhai Enterprises Ltd is 221 Cr..
What is the current Stock Price of Ambalal Sarabhai Enterprises Ltd as on 01 January 2026?
The current stock price of Ambalal Sarabhai Enterprises Ltd as on 01 January 2026 is ₹28.9.
What is the High / Low of Ambalal Sarabhai Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ambalal Sarabhai Enterprises Ltd stocks is ₹60.0/26.0.
What is the Stock P/E of Ambalal Sarabhai Enterprises Ltd?
The Stock P/E of Ambalal Sarabhai Enterprises Ltd is 14.2.
What is the Book Value of Ambalal Sarabhai Enterprises Ltd?
The Book Value of Ambalal Sarabhai Enterprises Ltd is 19.2.
What is the Dividend Yield of Ambalal Sarabhai Enterprises Ltd?
The Dividend Yield of Ambalal Sarabhai Enterprises Ltd is 0.00 %.
What is the ROCE of Ambalal Sarabhai Enterprises Ltd?
The ROCE of Ambalal Sarabhai Enterprises Ltd is 9.12 %.
What is the ROE of Ambalal Sarabhai Enterprises Ltd?
The ROE of Ambalal Sarabhai Enterprises Ltd is 6.25 %.
What is the Face Value of Ambalal Sarabhai Enterprises Ltd?
The Face Value of Ambalal Sarabhai Enterprises Ltd is 10.0.